AHCPR Becomes AHRQ, But Call It ARC

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Topline results from the phase 1/2 BEXMAB trial showed “one of the strongest data sets ever seen” in treatment-resistant higher-risk MDS populations.

Cristiane Decat Bergerot, PhD

April 14th 2025

Three Things You Should Know About Advances in Gastroesophageal Adenocarcinoma Therapy

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.

ONCOLOGY Staff

Elevating the Quality of Cancer Care via Cross-Department Collaboration

Immunotherapy combinations and targeted therapy options may help bridge clinical gaps in early-stage, locally advanced, and metastatic gastroesophageal adenocarcinomas.

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD

April 7th 2025

Daratumumab Combo Earns EU Approval in Newly Diagnosed Multiple Myeloma

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Data from the phase 3 CEPHEUS trial support the European Commission’s approval of the daratumumab-based regimen.

Tarlatamab Shows QOL, Symptom Benefits in Previously Treated SCLC

Data from the phase 3 CEPHEUS trial support the European Commission’s approval of the daratumumab-based regimen.

Patient-reported adverse effects associated with tarlatamab appeared to be generally mild in the phase 2 DeLLphi-301 trial.

Bexmarilimab/Chemo Yield Positive Responses in Myelodysplastic Syndromes

Patient-reported adverse effects associated with tarlatamab appeared to be generally mild in the phase 2 DeLLphi-301 trial.

Related Content

Tim Cortese

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Topline results from the phase 1/2 BEXMAB trial showed “one of the strongest data sets ever seen” in treatment-resistant higher-risk MDS populations.

Cristiane Decat Bergerot, PhD

April 14th 2025

Three Things You Should Know About Advances in Gastroesophageal Adenocarcinoma Therapy

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.

ONCOLOGY Staff

Elevating the Quality of Cancer Care via Cross-Department Collaboration

Immunotherapy combinations and targeted therapy options may help bridge clinical gaps in early-stage, locally advanced, and metastatic gastroesophageal adenocarcinomas.

Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD

April 7th 2025

Daratumumab Combo Earns EU Approval in Newly Diagnosed Multiple Myeloma

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Tarlatamab Shows QOL, Symptom Benefits in Previously Treated SCLC

Data from the phase 3 CEPHEUS trial support the European Commission’s approval of the daratumumab-based regimen.